Codes, Policies and Guidelines
Our Policies and Guidelines are a key element of our corporate responsibility. They define how we want to conduct business, what we expect of ourselves and our business partners throughout the world.
Our Policies contain governing principles and procedures to effectively manage a topic and are broadly applicable. They are updated every two years on average. Our Guidelines are subsidiary to Policies, where they exist, and to Code of Ethics topics otherwise. Guidelines clarify and amplify important principles and are based on best practices or mandatory rules. They are generally updated on an annual basis.
Ethics and compliance
Novartis Code of Ethics (PDF 4.1 MB)
Novartis Anti-Bribery Policy (PDF 0.3 MB)
Novartis Professional Practices Policy (PDF 1.0 MB)
Novartis Conflicts of Interest Policy (PDF 0.1 MB)
Governance
Novartis Corporate Responsibility Guideline (PDF 0.2 MB)
Health, safety, and environment
Novartis Global Health, Safety and Environment Policy (PDF 0.1 MB)
Human rights
Novartis Human Rights Guideline (PDF 0.1 MB)
Novartis Guideline on Non-Discrimination, Non-Harassment and Non-Retaliation (PDF 0.1 MB)
Novartis Global Parental Leave Guideline (PDF 0.2 MB)
Privacy
Novartis Data Privacy Principles (PDF 0.2 MB)
Novartis General Privacy Notice for Stakeholders (PDF 0.1 MB)
Novartis General Privacy Notice for Suppliers (PDF 0.1 MB)
Novartis General Privacy Notice for Business Partners (PDF 0.2 MB)
Research
Novartis Animal Welfare Policy (PDF 0.1 MB)
Novartis Publication Guidelines (PDF 0.2 MB)
Suppliers and third parties
Novartis Third Party Code v. 1.0 (PDF 0.6 MB)*
Novartis Third Party Code v. 2.0 (PDF 0.3 MB)**
Novartis Minimum Information Security Controls for Suppliers (PDF 0.1 MB)
Novartis COVID-19 Good Practice Guidance for Third Parties (PDF 0.3 MB)
*v1.0 remains valid for contracts entered into up to October 31, 2020
**v2.0 is valid for contracts entered into as from 1 November 2020
Novartis Annual Reporting Suite
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.